TORRENT PHARMACEUTICALS L vs Vanta Bioscience Ltd

A side-by-side comparison of TORRENT PHARMACEUTICALS L (TORNTPHARM) and Vanta Bioscience Ltd (VANTABIOSCIENCELTD) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, TORRENT PHARMACEUTICALS L leads TORNTPHARM vs VANTABIOSCIENCELTD on 11 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation31
  • Profitability31
  • Growth10
  • Size & financial health40
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

TORNTPHARM takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

77.60
P/E ratio
130.90
18.67
P/B ratio
0.66
0.76%
Dividend yield
0.00%
₹63.92
EPS
₹0.15

Profitability

TORNTPHARM takes 3/4

How efficiently each company turns capital and sales into profit. Higher is better.

27.40%
Return on equity
0.70%
15.00%
Return on capital
1.19%
33.00%
EBITDA margin
56.04%
15.29%
Net margin
6.04%

Growth

TORNTPHARM takes 1/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

13.27%
Revenue CAGR (3Y)
-32.16%
19.75%
Profit CAGR (3Y) even

Size & financial health

TORNTPHARM takes 4/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.88L Cr
Market cap
₹14 Cr
₹13,980 Cr
Revenue
₹2 Cr
₹2,138 Cr
Net profit
₹0 Cr
1.69
Debt / equity
1.80
TORRENT PHARMACEUTICALS L
  • + ["Company is expected to give good quarter", "Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
  • ["Stock is trading at 20.4 times its book value", "Promoter holding has decreased over last quarter: -7.53%", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
Vanta Bioscience Ltd
  • + ["Company has reduced debt.", "Stock is trading at 0.66 times its book value"]
  • ["Company has low interest coverage ratio.", "The company has delivered a poor sales growth of -28.6% over past five years.", "Company has a low return on equity of -15.6% over last 3 years.", "Company might be capitalizing the interest cost", "Company has high debtors of 513 days.", "Working capital days have increased from -636 days to 435 days"]
TORRENT PHARMACEUTICALS L full analysis Vanta Bioscience Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.